NEW YORK, May 6 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer Inc's drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.
Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel.
Analysts are forecasting annual sales to exceed $1 billion in 2024, according to Refinitiv data.
The FDA also approved another oral formulation of tafamidis under the brand name Vyndamax. (Reporting by Michael Erman, additional reporting by Manas Mishra in Bengaluru; Editing by Bill Berkrot)